Spero Therapeutics Past Earnings Performance
Past criteria checks 3/6
Spero Therapeutics has been growing earnings at an average annual rate of 34.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 52.1% per year. Spero Therapeutics's return on equity is 5.4%, and it has net margins of 3.3%.
Key information
34.1%
Earnings growth rate
43.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 52.1% |
Return on equity | 5.4% |
Net Margin | 3.3% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Jan 19There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Nov 02Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Jul 15Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04Revenue & Expenses Breakdown
How Spero Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 106 | 4 | 23 | 33 |
30 Jun 24 | 118 | 17 | 24 | 0 |
31 Mar 24 | 111 | 23 | 24 | 0 |
31 Dec 23 | 104 | 23 | 26 | 0 |
30 Sep 23 | 78 | -2 | 26 | 33 |
30 Jun 23 | 54 | -10 | 27 | 0 |
31 Mar 23 | 54 | -27 | 28 | 0 |
31 Dec 22 | 54 | -46 | 36 | 0 |
30 Sep 22 | 9 | -102 | 43 | 0 |
30 Jun 22 | 10 | -113 | 48 | 0 |
31 Mar 22 | 13 | -103 | 49 | 0 |
31 Dec 21 | 18 | -90 | 42 | 0 |
30 Sep 21 | 17 | -79 | 36 | 0 |
30 Jun 21 | 18 | -76 | 30 | 0 |
31 Mar 21 | 15 | -74 | 26 | 0 |
31 Dec 20 | 9 | -79 | 21 | 0 |
30 Sep 20 | 11 | -85 | 18 | 0 |
30 Jun 20 | 12 | -84 | 17 | 0 |
31 Mar 20 | 12 | -80 | 16 | 0 |
31 Dec 19 | 18 | -61 | 16 | 0 |
30 Sep 19 | 16 | -47 | 15 | 0 |
30 Jun 19 | 12 | -39 | 14 | 0 |
31 Mar 19 | 11 | -36 | 14 | 0 |
31 Dec 18 | 4 | -42 | 13 | 0 |
30 Sep 18 | 3 | -46 | 12 | 0 |
30 Jun 18 | 3 | -47 | 12 | 0 |
31 Mar 18 | 3 | -50 | 12 | 0 |
31 Dec 17 | 2 | -46 | 11 | 0 |
30 Sep 17 | 1 | -40 | 11 | 0 |
30 Jun 17 | 1 | -35 | 9 | 0 |
31 Mar 17 | 0 | -30 | 7 | 0 |
31 Dec 16 | 0 | -30 | 7 | 0 |
Quality Earnings: SPRO has high quality earnings.
Growing Profit Margin: SPRO became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPRO has become profitable over the past 5 years, growing earnings by 34.1% per year.
Accelerating Growth: SPRO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SPRO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: SPRO's Return on Equity (5.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/02 04:22 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Spero Therapeutics, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Esther Lannie Hong | Berenberg |
Jason Matthew Gerberry | BofA Global Research |
Joshua Schimmer | Evercore ISI |